Pingjun Chen
Overview
Explore the profile of Pingjun Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sujit S, Aminu M, Karpinets T, Chen P, Saad M, Salehjahromi M, et al.
Nat Commun
. 2024 Apr;
15(1):3152.
PMID: 38605064
While we recognize the prognostic importance of clinicopathological measures and circulating tumor DNA (ctDNA), the independent contribution of quantitative image markers to prognosis in non-small cell lung cancer (NSCLC) remains...
2.
Zafar A, Aftab D, Qureshi R, Fan X, Chen P, Wu J, et al.
IEEE Trans Image Process
. 2024 Apr;
33:2924-2935.
PMID: 38598372
Recently attention-based networks have been successful for image restoration tasks. However, existing methods are either computationally expensive or have limited receptive fields, adding constraints to the model. They are also...
3.
Salehjahromi M, Karpinets T, Sujit S, Qayati M, Chen P, Aminu M, et al.
Cell Rep Med
. 2024 Mar;
5(3):101463.
PMID: 38471502
[F]Fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) are indispensable components in modern medicine. Although PET can provide additional diagnostic value, it is costly and not universally accessible, particularly...
4.
Automated Cellular-Level Dual Global Fusion of Whole-Slide Imaging for Lung Adenocarcinoma Prognosis
Diao S, Chen P, Showkatian E, Bandyopadhyay R, Rojas F, Zhu B, et al.
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835518
Histopathologic whole-slide images (WSI) are generally considered the gold standard for cancer diagnosis and prognosis. Survival prediction based on WSI has recently attracted substantial attention. Nevertheless, it remains a central...
5.
Chen P, Rojas F, Hu X, Serrano A, Zhu B, Chen H, et al.
Mod Pathol
. 2023 Sep;
36(12):100326.
PMID: 37678674
Recent statistics on lung cancer, including the steady decline of advanced diseases and the dramatically increasing detection of early-stage diseases and indeterminate pulmonary nodules, mark the significance of a comprehensive...
6.
Saad M, Hong L, Aminu M, Vokes N, Chen P, Salehjahromi M, et al.
Lancet Digit Health
. 2023 Jun;
5(7):e404-e420.
PMID: 37268451
Background: Only around 20-30% of patients with non-small-cell lung cancer (NCSLC) have durable benefit from immune-checkpoint inhibitors. Although tissue-based biomarkers (eg, PD-L1) are limited by suboptimal performance, tissue availability, and...
7.
Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad M, et al.
Nat Commun
. 2023 Feb;
14(1):695.
PMID: 36755027
The role of combination chemotherapy with immune checkpoint inhibitors (ICI) (ICI-chemo) over ICI monotherapy (ICI-mono) in non-small cell lung cancer (NSCLC) remains underexplored. In this retrospective study of 1133 NSCLC...
8.
Aminu M, Yadav D, Hong L, Young E, Edelkamp Jr P, Saad M, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612278
Objectives: Cancer patients have worse outcomes from the COVID-19 infection and greater need for ventilator support and elevated mortality rates than the general population. However, previous artificial intelligence (AI) studies...
9.
Chen P, Zhang J, Wu J
21 Century Pathol
. 2022 Oct;
2(3).
PMID: 36282981
Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of many malignancies. For instance, in lung cancer, however, only 2030% of patients can achieve durable clinical benefits from ICI monotherapy. Histopathologic and...
10.